Seeking the right targets: Gene therapy advances in pulmonary arterial hypertension

European Respiratory Journal

Volumn 39, Issue 2, 2012, Pages 235-237

  Machado, R D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA; VASODILATOR AGENT;

BLOOD VESSEL REACTIVITY; BMPR2 GENE; DISEASE COURSE; DRUG EFFICACY; EDITORIAL; GENE; GENE MUTATION; GENE TARGETING; GENE THERAPY; GENETIC DISORDER; HEART FAILURE; HUMAN; HYPOXIA; LUNG ARTERY PRESSURE; LUNG CAPILLARY; LUNG ENDOTHELIUM; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MEAN ARTERIAL PRESSURE; PALLIATIVE THERAPY; PENETRANCE; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION; PULMONARY HYPERTENSION; SURVIVAL RATE; SURVIVAL TIME; VASCULAR ENDOTHELIUM; VASOCONSTRICTION;

ANIMALS; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; GENE THERAPY; HUMANS; HYPERTENSION, PULMONARY; MALE;

EID: 84856750128     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00190011     Document Type: Editorial

References (25)

1. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-1263.
2. Austin ED, Loyd JE, Phillips JA 3rd. Genetics of pulmonary arterial hypertension. Semin Respir Crit Care Med 2009; 30: 386-398.
3. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. Nat Genet 2000; 26: 81-84.
4. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67: 737-744. (Pubitemid 30659603)
5. Machado RD, Eickelberg O, Elliott CG, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S32-S42.
6. Aldred MA, Vijayakrishnan J, James V, et al. BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Hum Mutat 2006; 27: 212-213.
7. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S43-S54.
8. Machado RD, Pauciulo MW, Thomson JR, et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001; 68: 92-102. (Pubitemid 32048364)
9. Atkinson C, Stewart S, Upton PD, et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002; 105: 1672-1678. (Pubitemid 34298611)
10. Takahashi H, Goto N, Kojima Y, et al. Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2006; 290: L450-L458. (Pubitemid 43725089)
11. Morty RE, Nejman B, Kwapiszewska G, et al. Dysregulated bone morphogenetic protein signaling in monocrotaline-induced pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2007; 27: 1072-1078. (Pubitemid 46641959)
12. Miyazono K, Kamiya Y, Morikawa M. Bone morphogenetic protein receptors and signal transduction. J Biochem 2010; 147: 35-51.
13. Upton PD, Davies RJ, Trembath RC, et al. Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells. J Biol Chem 2009; 284: 15794-15804.
14. Harrison RE, Flanagan JA, Sankelo M, et al. Molecular and functional analysis identifies ALK-1 as the predominant cause ofpulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet 2003; 40: 865-871. (Pubitemid 38117534)
15. Girerd B, Montani D, Coulet F, et al. Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med 2010; 181: 851-861.
16. Fujiwara M, Yagi H, Matsuoka R, et al. Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension. Circ J 2008; 72: 127-133. (Pubitemid 351413340)
17. Shintani M, Yagi H, Nakayama T, et al. A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension. J Med Genet 2009; 46: 331-337.
18. Nasim MT, Ogo T, Ahmed M, et al. Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Hum Mutat 2011; 32: 1385-1389.
19. Long L, Crosby A, Yang X, et al. Altered bone morphogenetic protein and transforming growth factor-β signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation 2009; 119: 566-576.
20. Agarwal R, Gomberg-Maitland M. Current therapeutics and practical management strategies for pulmonary arterial hypertension. Am Heart J 2011; 162: 201-213.
21. Corris PA. Alternatives to lung transplantation: treatment of pulmonary arterial hypertension. Clin Chest Med 2011; 32: 399-410.
22. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
23. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164-172.
24. Humbert M, Sitbon O, Yaïci A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010; 36: 549-555.
25. Reynolds AM, Holmes MD, Danilov SM, et al. Targeted gene delivery of BMPR2 attenuates pulmonary hypertension. Eur Respir J 2012; 39: 329-343.